CD274 and breast carcinoma: PD‐L1 has association with prognosis and resistance across multiple cancer types, including lung cancer (Patil et al., 2022), melanoma cancer (Serratì et al., 2022), bladder cancer (Jing et al., 2022), and breast cancer (Vranic et al., 2021).